Department of Biological Sciences, National University of Singapore, Singapore 117543.
Mol Cell Proteomics. 2011 Mar;10(3):M110.004390. doi: 10.1074/mcp.M110.004390. Epub 2010 Nov 16.
The regulatory (R) subunit of protein kinase A serves to modulate the activity of protein kinase A in a cAMP-dependent manner and exists in two distinct and structurally dissimilar, end point cAMP-bound "B" and C-subunit-bound "H"-conformations. Here we report mechanistic details of cAMP action as yet unknown through a unique approach combining x-ray crystallography with structural proteomics approaches, amide hydrogen/deuterium exchange and ion mobility mass spectrometry, applied to the study of a stereospecific cAMP phosphorothioate analog and antagonist((Rp)-cAMPS). X-ray crystallography shows cAMP-bound R-subunit in the B form but surprisingly the antagonist Rp-cAMPS-bound R-subunit crystallized in the H conformation, which was previously assumed to be induced only by C-subunit-binding. Apo R-subunit crystallized in the B form as well but amide exchange mass spectrometry showed large differences between apo, agonist and antagonist-bound states of the R-subunit. Further ion mobility reveals the apo R-subunit as an ensemble of multiple conformations with collisional cross-sectional areas spanning both the agonist and antagonist-bound states. Thus contrary to earlier studies that explained the basis for cAMP action through "induced fit" alone, we report evidence for conformational selection, where the ligand-free apo form of the R-subunit exists as an ensemble of both B and H conformations. Although cAMP preferentially binds the B conformation, Rp-cAMPS interestingly binds the H conformation. This reveals the unique importance of the equatorial oxygen of the cyclic phosphate in mediating conformational transitions from H to B forms highlighting a novel approach for rational structure-based drug design. Ideal inhibitors such as Rp-cAMPS are those that preferentially "select" inactive conformations of target proteins by satisfying all "binding" constraints alone without inducing conformational changes necessary for activation.
蛋白激酶 A 的调节(R)亚基以 cAMP 依赖性方式调节蛋白激酶 A 的活性,并且存在两种不同的、结构上不同的、终点 cAMP 结合的“B”和 C 亚基结合的“H”构象。在这里,我们通过一种独特的方法结合 X 射线晶体学与结构蛋白质组学方法、酰胺氢/氘交换和离子淌度质谱,报道了 cAMP 作用的机制细节,这些细节以前未知,应用于立体特异性 cAMP 硫代磷酸酯类似物和拮抗剂((Rp)-cAMPS)的研究。X 射线晶体学显示 cAMP 结合的 R 亚基呈 B 构象,但令人惊讶的是,拮抗剂 Rp-cAMPS 结合的 R 亚基结晶呈 H 构象,而此前认为只有 C 亚基结合才能诱导 H 构象。无配体的 R 亚基也结晶呈 B 构象,但酰胺交换质谱显示,R 亚基的无配体、激动剂和拮抗剂结合状态之间存在很大差异。进一步的离子淌度显示,apo R 亚基作为多个构象的集合存在,碰撞截面面积跨越激动剂和拮抗剂结合状态。因此,与早期研究通过“诱导契合”单独解释 cAMP 作用的基础不同,我们报告了构象选择的证据,其中 R 亚基的无配体 apo 形式作为 B 和 H 构象的集合存在。虽然 cAMP 优先结合 B 构象,但 Rp-cAMPS 有趣地结合 H 构象。这揭示了环磷酸酯的赤道氧在介导从 H 到 B 构象的构象转变中的独特重要性,突出了一种新的基于结构的合理药物设计方法。理想的抑制剂,如 Rp-cAMPS,是那些仅通过满足所有“结合”约束来优先“选择”靶蛋白的无活性构象,而无需诱导激活所需的构象变化的抑制剂。